The Medicines Company (NASDAQ:MDCO) has been assigned an average rating of “Buy” from the thirteen brokerages that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $51.00.
Several brokerages recently weighed in on MDCO. BidaskClub upgraded The Medicines from a “sell” rating to a “hold” rating in a research note on Thursday. Oppenheimer set a $50.00 target price on The Medicines and gave the company a “buy” rating in a research note on Monday, March 12th. ValuEngine upgraded The Medicines from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Jefferies Group reiterated a “buy” rating and issued a $47.00 price objective on shares of The Medicines in a research report on Friday, February 23rd. Finally, Zacks Investment Research upgraded The Medicines from a “hold” rating to a “buy” rating and set a $34.00 price objective for the company in a research report on Tuesday, February 6th.
Institutional investors and hedge funds have recently modified their holdings of the company. Quantbot Technologies LP acquired a new position in shares of The Medicines in the 3rd quarter worth approximately $171,000. SG Americas Securities LLC raised its holdings in shares of The Medicines by 33.8% in the 4th quarter. SG Americas Securities LLC now owns 7,145 shares of the company’s stock worth $195,000 after buying an additional 1,805 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of The Medicines in the 4th quarter worth approximately $202,000. Elkfork Partners LLC acquired a new position in shares of The Medicines in the 4th quarter worth approximately $214,000. Finally, Xact Kapitalforvaltning AB acquired a new position in shares of The Medicines in the 4th quarter worth approximately $218,000.
The Medicines (NASDAQ:MDCO) traded down $0.31 on Friday, hitting $33.19. The stock had a trading volume of 1,218,718 shares, compared to its average volume of 1,470,609. The company has a market cap of $2,432.30, a P/E ratio of -3.38 and a beta of 0.74. The Medicines has a 52 week low of $24.45 and a 52 week high of $55.95. The company has a debt-to-equity ratio of 26.06, a quick ratio of 3.18 and a current ratio of 3.21.
The Medicines (NASDAQ:MDCO) last announced its earnings results on Wednesday, February 21st. The company reported ($2.19) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.71). The Medicines had a negative net margin of 1,035.27% and a negative return on equity of 316.40%. The business had revenue of $8.60 million for the quarter, compared to the consensus estimate of $20.71 million. During the same quarter in the previous year, the company earned ($1.19) EPS. The Medicines’s revenue for the quarter was down 50.6% compared to the same quarter last year. research analysts predict that The Medicines will post -2.71 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “The Medicines Company (MDCO) Receives Average Rating of “Buy” from Brokerages” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/03/18/the-medicines-company-mdco-receives-average-rating-of-buy-from-brokerages.html.
The Medicines Company Profile
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.